Heart transplant drug may shield kidneys from failure
NCT ID NCT04180085
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug belatacept can protect kidney function in heart transplant patients who are at high risk of chronic kidney disease. About 25 adults who had a heart transplant 3 months ago and have declining kidney function will receive belatacept along with reduced doses of standard anti-rejection drugs. The goal is to see if this approach can slow kidney damage and reduce the need for dialysis or a kidney transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANT FAILURE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bertrand Lelong
RECRUITINGRennes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Claire Garandeau
RECRUITINGNantes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karine Nubret
RECRUITINGBordeaux, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Laurent Sebbag
RECRUITINGLyon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.